# PRaG Regimens Rechallenge for Patients With Resistance to PD1/PD-L1 Inhibitors in Refractory Advanced Solid Tumors.

> **NCT05530200** · PHASE2 · UNKNOWN · sponsor: **Second Affiliated Hospital of Soochow University** · enrollment: 56 (estimated)

## Conditions studied

- Metastatic Solid Tumor

## Interventions

- **RADIATION:** Hypofractionated radiotherapy
- **DRUG:** PD-L1 inhibitor
- **DRUG:** GM-CSF
- **DRUG:** IL-2

## Key facts

- **NCT ID:** NCT05530200
- **Lead sponsor:** Second Affiliated Hospital of Soochow University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-09
- **Primary completion:** 2024-12
- **Final completion:** 2025-06
- **Target enrollment:** 56 (ESTIMATED)
- **Last updated:** 2022-09-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05530200

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05530200, "PRaG Regimens Rechallenge for Patients With Resistance to PD1/PD-L1 Inhibitors in Refractory Advanced Solid Tumors.". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT05530200. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*